Key result
High-intensity statin and fibrate therapy improves dyslipidemia and proteinuria in a lipoprotein glomerulopathy case.
Why the study?
Severe hyperlipidemia requires extensive evaluation to identify rare causes such as lipoprotein glomerulopathy associated with apolipoprotein E dyslipidemia.
Case Report (n=1)
High-intensity statin and fibrate therapy can effectively improve dyslipidemia and proteinuria in patients with lipoprotein glomerulopathy associated with the apolipoprotein E3/E4 phenotype.
Statin-fibrate may benefit lipoprotein glomerulopathy; single case leaves efficacy, safety, and generalizability unproven.
Severe hyperlipidemia warrants an extensive evaluation. We report a case of a 25-year-old man of Chinese descent seen in the cardiology-lipid clinic. He was found to have a serum low-density lipoprotein cholesterol of 12.12 mmol/L (468 mg/dL) and serum triglycerides of 2.29 mmol/L (203 mg/dL) during routine screening. Work-up revealed nephrotic-range proteinuria, and renal biopsy showed dilated glomerular capillary loops with lipid deposits, pathognomonic of lipoprotein glomerulopathy. Genetic studies showed apolipoprotein E3/E4 phenotype. He was treated with a high-intensity statin and fibrate therapy, which resulted in a marked improvement in dyslipidemia and proteinuria.
No takes yet. Share an insight, caveat, or question.
Tito et al. (2023) conducted a case report in Severe hyperlipidemia and nephrotic syndrome (lipoprotein glomerulopathy) (n=1). High-intensity statin and fibrate therapy was evaluated on Improvement in dyslipidemia and proteinuria. Treatment with a high-intensity statin and fibrate therapy resulted in a marked improvement in dyslipidemia and proteinuria in a patient with lipoprotein glomerulopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: